TY - JOUR
T1 - NASPGHAN clinical report
T2 - Surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-α inhibitors
AU - Ardura, Monica I.
AU - Toussi, Sima S.
AU - Siegel, Jane D.
AU - Lu, Ying
AU - Bousvaros, Athos
AU - Crandall, Wallace
N1 - Publisher Copyright:
© 2016 by ESPGHAN and NASPGHAN.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Children and adolescents with inflammatory bowel disease (IBD) receiving therapy with tumor necrosis factor α inhibitors (anti-TNFα) pose a unique challenge to health care providers in regard to the associated risk of infection. Published experience in adult populations with distinct autoinflammatory and autoimmune diseases treated with anti-TNFα therapies demonstrates an increased risk of serious infections with intracellular bacteria, mycobacteria, fungi, and some viruses; however, there is a paucity of robust pediatric data. With a rising incidence of pediatric IBD and increasing use of biologic therapies, heightened knowledge and awareness of infections in this population is important for primary care pediatricians, pediatric gastroenterologists, and infectious disease (ID) physicians. This clinical report is the result of a consensus review performed by pediatric ID and gastroenterology physicians detailing relevant published literature regarding infections in pediatric patients with IBD receiving anti-TNFα therapies. The objective of this document is to provide comprehensive information for prevention, surveillance, and diagnosis of infections based on current knowledge, until additional pediatric data are available to inform evidence-based recommendations.
AB - Children and adolescents with inflammatory bowel disease (IBD) receiving therapy with tumor necrosis factor α inhibitors (anti-TNFα) pose a unique challenge to health care providers in regard to the associated risk of infection. Published experience in adult populations with distinct autoinflammatory and autoimmune diseases treated with anti-TNFα therapies demonstrates an increased risk of serious infections with intracellular bacteria, mycobacteria, fungi, and some viruses; however, there is a paucity of robust pediatric data. With a rising incidence of pediatric IBD and increasing use of biologic therapies, heightened knowledge and awareness of infections in this population is important for primary care pediatricians, pediatric gastroenterologists, and infectious disease (ID) physicians. This clinical report is the result of a consensus review performed by pediatric ID and gastroenterology physicians detailing relevant published literature regarding infections in pediatric patients with IBD receiving anti-TNFα therapies. The objective of this document is to provide comprehensive information for prevention, surveillance, and diagnosis of infections based on current knowledge, until additional pediatric data are available to inform evidence-based recommendations.
KW - infections
KW - pediatric inflammatory bowel disease
KW - tumor necrosis factor α inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84961950240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961950240&partnerID=8YFLogxK
U2 - 10.1097/MPG.0000000000001188
DO - 10.1097/MPG.0000000000001188
M3 - Article
C2 - 27027903
AN - SCOPUS:84961950240
SN - 0277-2116
VL - 63
SP - 130
EP - 155
JO - Journal of pediatric gastroenterology and nutrition
JF - Journal of pediatric gastroenterology and nutrition
IS - 1
ER -